Abstract:Swati Jain ^ , Kevin Ma, Luc G. T. Morris Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA ^ ORCID: 0000-0002-8625-8218. Comment on: Moutafi M, Martinez-Morilla S, Divakar P, et al . Discovery of Biomarkers of Resistance to Immune Checkpoint Blockade in NSCLC Using High-Plex Digital Spatial Profiling. J Thorac Oncol 2022;17:991-1001. Keywords: Non-small cell lung cancer (NSCLC); digital spatial profiling; biomarker; CD66b; tumor associated neutrophils Submitted Dec 23, 2022. Accepted for publication Jan 09, 2023. Published online Feb 21, 2023. doi: 10.21037/tcr-22-2880 Non-small cell lung cancer (NSCLC) is the leading cause of cancer death around the world, including in the United States, where it is the leading cause of cancer-related mortality in both men and women. In recent years, the introduction of immune checkpoint inhibitors (ICI) has transformed the landscape of immunotherapy and opened up new treatment options for advanced stage (unresectable stage III and stage IV) NSCLC of both adenocarcinoma and squamous cell carcinoma histologies. Anti-PD-1/PD-L1 antibodies have demonstrated a significant benefit to a subset of patients, but a majority of patients do not respond to these antibodies or develop progressive disease after an initial clinical response. Patients who do not experience durable tumor response from ICI are exposed to potential immune-related toxicity, and the health system to financial costs, without benefit. Resistance to immunotherapy, either inherent or acquired, remains a significant challenge in improving ICI efficacy. In addition, better predictive biomarkers are needed to inform clinical care, and potentially triage patients who are unlikely to benefit from ICI to other therapies that may offer greater benefit (1). Currently, PD-L1 expression is the most widely used biomarker for stratification of ICI treatment in NSCLC. However, PD-L1 expression is an imperfect biomarker due to inconsistencies such as variability in quantification methods and a lack of standardized cut-off points. As a result, PD-L1 immunohistochemistry may be used to determine eligibility for ICI therapies (e.g., PD-L1 TPS score >1%), but its role as a predictive marker has been observed to be limited, with an area under the receiving operating curve of <0.7 (2,3). Further optimization of this biomarker is required to improve its sensitivity and reproducibility. One emerging area of interest in biomarker discovery is the use of neutrophils, which have been shown to be instrumental in modulating the tumor microenvironment (TME). Tumor-associated neutrophils (TANs) in the TME have been implicated in cancer progression and serve as an independent prognostic factor of unfavorable outcomes in a wide variety of cancer types (4,5). Tumor cells can alter the differentiation of TANs for their own benefit, promoting pro-tumor mechanisms, such as tumor angiogenesis, immune suppression, and neutrophil extracellular trap formation. The detection of pro-tumor TANs and TAN activity are associated with lower rates of response to ICI treatment (6). On the other hand, TANs have also been described to have some important anti-tumor functions, especially in the early stages of tumorigenesis. They can directly induce tumor cell apoptosis through secretion of cytotoxic molecules and target opsonized tumor cells via antibody-dependent cellular cytotoxicity (4). Thus, TAN associated markers could be promising targets for biomarker discovery for cancer prognosis and resistance to therapies. CD66b, a granulocyte activation marker typically found on neutrophils and eosinophils, may have predictive value in patients treated with immunotherapy. In a recent study authored by Moutafi and colleagues at Yale School of Medicine, the authors sought to evaluate new candidate biomarkers for ICI response and resistance in NSCLC, using digital spatial profiling (DSP) (7). To investigate this, the authors used the recently developed NanoString GeoMX DSP technology, which combines standard immunostaining with digitally countable DNA barcodes, thereby allowing quantification of protein markers in specific regions of interest (ROIs). Leveraging this platform, Moutafi et al. studied the immune microenvironment of advanced NSCLC tumors from 56 patients treated at Yale with ICI. With DSP techniques, 284 protein biomarkers were analyzed. Analyses focused on 71 validated immune-oncology markers assessed in four molecular compartments—macrophage (CD68 + ), leukocyte (CD45 + /CD68 − ), tumor cell (panCK), and immune stroma (panCK − /CD45 + /CD68 + ). Of these proteins, CD66b was found to have a statistically significant association with poorer outcome; specifically, higher levels of CD66b in the immune stroma compartment were associated with shorter overall s -Abstract Truncated-

Spatially resolved proteomic profiling identifies tumor cell CD44 as a biomarker associated with sensitivity to PD-1 axis blockade in advanced non-small-cell lung cancer

CD57+CD8+T Cells and Response to PD-1/PD-L1 Blockade in Patients with NSCLC

Predictive Effect of Spatial Protein Signature in Advanced Non-small Cell Lung Cancer Patients Treated with Bispecific Antibody (KN046) Immunotherapy

Longitudinal High-Dimensional Analysis Identifies Biomarkers of Response to Anti-PD-1 Immunotherapy

Intratumoral CD39+CD8+ T Cells Predict Response to Programmed Cell Death Protein-1 or Programmed Death Ligand-1 Blockade in Patients With NSCLC

Digital spatial profiling links beta-2-microglobulin expression with immune checkpoint blockade outcomes in head and neck squamous cell carcinoma

Immune cell topography predicts response to PD-1 blockade in cutaneous T cell lymphoma

Role of tumor infiltrating lymphocytes and spatial immune heterogeneity in sensitivity to PD-1 axis blockers in non-small cell lung cancer

Data from Immune-Related Gene Expression Profiling after PD-1 Blockade in Non–Small Cell Lung Carcinoma, Head and Neck Squamous Cell Carcinoma, and Melanoma

A Subset of PD-1-Expressing CD56bright NK Cells Identifies Patients with Good Response to Immune Checkpoint Inhibitors in Lung Cancer

High-throughput transcriptome profiling indicates ribosomal RNAs to be associated with resistance to immunotherapy in non-small cell lung cancer (NSCLC)

CD34 as a potential prognostic indicator for camrelizumab response in advanced non-small-cell lung cancer: insights from digital spatial profiling

Abstract PR-01: Distinct CD4+ T cell subpopulations as predictive biomarkers for anti-PD-1 and chemotherapy response in advanced NSCLC

Immunoscore immune checkpoint using spatial quantitative analysis of CD8 and PD-L1 markers is predictive of the efficacy of anti- PD1/PD-L1 immunotherapy in non-small cell lung cancer

PD-1 expression in tumor infiltrating lymphocytes as a prognostic marker in early-stage non-small cell lung cancer

CD66b as a prognostic and predictive biomarker in patients with non-small cell lung cancer treated with checkpoint blockade immunotherapy

Abstract PR-08: Spatial transcriptomics to profile the non-small cell lung cancer tumor microenvironment and identify novel predictive biomarkers for checkpoint blockade

CD137+ and regulatory T cells as independent prognostic factors of survival in advanced non-oncogene addicted NSCLC patients treated with immunotherapy as first-line

Blood-based molecular and cellular biomarkers of early response to neoadjuvant PD-1 blockade in patients with non-small cell lung cancer

PD-L1 Expression in Systemic Immune Cell Populations as a Potential Predictive Biomarker of Responses to PD-L1/PD-1 Blockade Therapy in Lung Cancer

Abstract 6391: Spatial proteomic profiling unveils pre-existing anti-tumor immunity as a hallmark of exceptional benefit from immunotherapy in NSCLC